HIV-1 elite controllers present a high frequency of activated regulatory T and Th17 cells

Diogo G. Caetano, Hury H. S. de Paula, Gonzalo Bello, Brenda Hoagland, Larissa M. Villela, Beatriz Grinsztejn, Valdilea G. Veloso, Mariza G. Morgado, Monick L. Guimarães, Fernanda H. Côrtes

1 Laboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz–IOC, FIOCRUZ, Rio de Janeiro, Brazil, 2 Instituto Nacional de Infectologia Evandro Chagas—INI, FIOCRUZ, Rio de Janeiro, Brazil

* fheloise@ioc.fiocruz.br, fheloise@gmail.com

Abstract

HIV-1 infection is characterized by generalized deregulation of the immune system, resulting in increased chronic immune activation. However, some individuals called HIV controllers (HICs) present spontaneous control of viral replication and have a more preserved immune system. Among HICs, discordant results have been observed regarding immune activation and the frequency of different T cell subsets, including Treg and Th17 cells. We evaluated T cell immune activation, differentiation and regulatory profiles in two groups of HICs—elite controllers (ECs) and viremic controllers (VCs)—and compared them to those of cART-treated individuals (cART) and HIV-1-negative (HIV-neg) individuals. ECs demonstrated similar levels of activated CD4+ and CD8+ T cells in comparison to HIV-neg, while cART and VCs showed elevated T cell activation. CD4+ T cell subset analyses showed differences only for transitional memory T cell frequency between the EC and HIV-neg groups. However, VC individuals showed higher frequencies of terminally differentiated, naïve, and stem cell memory T cells and lower frequencies of transitional memory and central memory T cells compared to the HIV-neg group. Among CD8+ T cell subsets, ECs presented higher frequencies of stem cell memory T cells, while VCs presented higher frequencies of terminally differentiated T cells compared to the HIV-neg group. HICs showed lower frequencies of total Treg cells compared to the HIV-neg and cART groups. ECs also presented higher frequencies of activated and a lower frequency of resting Treg cells than the HIV-neg and cART groups. Furthermore, we observed a high frequency of Th17 cells in ECs and high Th17/Treg ratios in both HIC groups. Our data showed that ECs had low levels of activated T cells and a high frequency of activated Treg and Th17 cells, which could restrict chronic immune activation and be indicative of a preserved mucosal response in these individuals.
Introduction

HIV-1 controllers (HICs) are a rare group of HIV-1-infected individuals able to spontaneously control viral replication in the absence of combined antiretroviral therapy (cART). Classically, these individuals are divided into two groups: Elite controllers (ECs), who are able to keep plasma viral loads below the detection limit of clinical assays (currently < 40 HIV-1 RNA copies/ml), and viremic controllers (VCs), who present plasma viral loads < 2,000 HIV-1 RNA copies/ml [1].

HIV-1 infection is characterized by generalized deregulation of the immune system, resulting in high levels of chronic immune activation [2,3], which has been described as a state of increased cellular turnover, cell cycle deregulation and establishment of an inflammatory setting [2,4] that is not fully normalized even after initiation of cART [5–8]. Moreover, alterations in the frequency of different T cell subsets, leading to an increase in effector or fully differentiated T cells [2,4,9–11] and a decrease in naïve T cells [2,10,12,13], have also been observed as a consequence of the chronic immune activation. Despite the viremia control, some HICs present higher levels of immune activation and inflammation than HIV-1-uninfected individuals [14–16], mainly the VC individuals [17,18].

In addition to alterations in the frequency of naïve, effector and memory T cells, the chronic phase of HIV infection has been associated with an increased frequency of regulatory T cells (Treg) [19–28], which are a subset of CD4+ T cells that regulate the immune response and the proliferation of effector T cells [29–31]. In the context of HIV-1 infection, the immunosuppressive function of Treg cells has been described to have both detrimental and protective effects on disease progression. Higher frequencies of Treg cells correlate with high plasma viral load and progression to AIDS [19–28], while lower frequencies have been observed for HICs/long-term nonprogressors (LTNPs) [32–35] and cART-treated patients [25,26,28,35,36] and are associated with an increase in viral-specific CD8+ T cell response [37–41]. On the other hand, higher frequencies of Treg cells are associated with a decrease in the systemic immune activation [28,35,42].

Another T cell subset affected during HIV-1 infection is Th17 cells. These cells are enriched in the mucosal tissues and classically produce a set of proinflammatory cytokines (e.g., IL-17, IL-22, IL-21) [43–45] that enhance the expression of antimicrobial peptides [46], recruit neutrophils [47,48] and induce epithelial regeneration [49], thus playing an essential role in the host defense against microbial pathogens and maintenance of epithelial integrity at mucosal sites. Th17 cells are preferentially depleted during the acute phase in pathogenic SIV models [50–52] but preserved in nonpathogenic infection [51,53], and a lower frequency of these cells is observed during the chronic phase in HIV-infected patients with progressive disease [53–56].

Despite their opposite functions, both the Treg and Th17 subsets are derived from a common progenitor cell, with their formation determined by the expression levels of IL-6 and TGF-β [57]. Thus, inverse and reciprocal alterations in both subsets have been observed in the context of HIV-1 infection, and the loss of the balance between these two populations has been associated with disease progression [32–34,51]. In contrast, higher Th17/Treg ratios have been observed in ECs compared to typical progressors [32–34].

In the present study, we aimed to evaluate parameters related to the immune activation, memory T cells, and regulatory T cells in HICs and the distribution of different T cell subsets involved in the immune response. Beyond the frequencies of activated T cells, we evaluated the frequencies of naïve, stem cell memory, central memory, transitional memory, effector memory and terminally differentiated T cells in both ECs and VCs, comparing with the frequencies observed for HIV-negative individuals and cART-treated individuals. We also evaluated the
frequencies of total Tregs and their different subsets, as well as the frequencies of Th17 cells to assess the Th17/Treg balance. Our data showed that ECs had low levels of activated T cells and a high frequency of activated Treg cells, which could contribute to lower immune activation in these individuals. Additionally, a higher frequency of Th17 cells in ECs might be indicative of preserved mucosal response resulting in low microbial translocation and immune activation.

Materials and methods

Study population and ethical statement

Twenty-seven HICs were selected from the Instituto Nacional de Infectologia Evandro Chagas/Fiocruz (INI-Fiocruz) HIV-1 cohort for this study and were classified into two groups: (1) ECs (n = 14) if the plasma viral load (VL) measurements were below the lower detection limit (<LDL) depending on the commercial method available during the clinical and laboratory follow-up (< 50–80 copies/ml) and (2) VCs (n = 13), if most (≥ 70%) VL measurements were >LDL and <2,000 copies/ml. Occasional VL measurements above the upper limits were accepted during the follow-up of the EC and VC groups. A group of HIV-1-infected individuals on cART with a suppressed VL for at least two years (cART; n = 18) and a group of HIV-1-uninfected individuals (HIV-neg; n = 18) were also included as controls. All participants provided written informed consent, and both the INI-Fiocruz Ethical Committee Board and the Brazilian National Human Research Ethics Committee (CONEP 840/2008) approved the study.

Sample preparation

Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by Histopaque-1077 (Sigma-Aldrich, USA) density gradient centrifugation and stored in liquid nitrogen until use.

CD4⁺ and CD8⁺ T cell count and plasma VL determination

Absolute CD4⁺ and CD8⁺ T cell counts were obtained from whole blood using the MultiTest TruCount-kit and the MultiSet software on a FACSCalibur flow cytometer (BD Biosciences, USA). Plasma HIV-1 viral loads of the samples corresponding to the time points analyzed in the present study were measured using the Abbott RealTime HIV-1 assay (Abbott Laboratories, Germany), with LDL of 40 copies/ml.

Flow cytometry

For each patient, vials of 1x10⁷ cryopreserved PBMCs with viability >85% were thawed and rested overnight in RPMI 1640 (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS, Gibco —Thermo Fisher Scientific, USA) at 37°C with 5% of CO₂ and controlled humidity. For naïve, memory, effector and activated CD4⁺ and CD8⁺ T cell subsets, detailed below, PBMCs were stained with FVS450 (BD Biosciences, USA) for dead cells exclusion, and with anti-CD3 APC-H7, anti-CD4 PE-CF594, anti-CD8 APC, anti-CD45RA PE-Cy7, anti-CD27 BV510, anti-CCR7 Alexa Fluor 700, anti-CD95 PerCP-Cy5.5, anti- HLA-DR PE and anti-CD38 BB515 (all from BD Biosciences, USA). The T cell activation status was evaluated based on the analysis of CD38 and HLA-DR coexpression, while T cell subsets were classified as follows: naïve (TN: CD45RA⁺CCR7⁺CD27⁺CD95⁻), stem cell memory (TSCM: CD45RA⁺CCR7⁺CD27⁺CD95⁻), central memory (TCM: CD45RA⁺CCR7⁺CD27⁻), transitional memory (TTM: CD45RA⁺CCR7⁻CD27⁻), effector memory (TEM: CD45RA⁺CCR7⁻CD27⁻), and effector or terminally differentiated (TEFF: CD45RA⁺CCR7⁻CD27⁻).
FMO controls were used to properly identify the CD45RA+, CCR7+, CD27+, CD38+ and HLA-DR+ populations. For Treg and Th17 cell frequencies determination, PBMCs were stimulated with PMA and ionomycin (50 ng/ml and 1 μg/ml, respectively; Sigma-Aldrich, USA) in the presence of Golgi Stop (Human Th17/Treg Phenotyping Kit; BD Biosciences, USA) according to the manufacturer’s instructions, for five hours. The cells were stained with FVS450, anti-CD25-BB515, and anti-CD8-BV510 (all from BD Biosciences, USA). After, the cells were washed with staining buffer (2% of FBS in PBS) and fixed using the Human FoxP3 Buffer A (Human Th17/Treg Phenotyping Kit; BD Biosciences, USA). Subsequently, the cells were washed and incubated with a staining buffer at 4°C overnight. Then, the cells were permeabilized using Human FoxP3 Buffer C (Human Th17/Treg Phenotyping Kit; BD Biosciences, USA) and stained with anti-CD3-APC-H7, anti-CD45RA-PeCy7 and Human FoxP3 cocktail (Human Th17/Treg Phenotyping Kit; BD Biosciences, USA). Samples were acquired on the same day using a BD FACSAria™ IIu flow cytometer (BD Biosciences, USA), and analyses were performed with FlowJo software v.10.0.7 (Tree Star, USA). Th17 cells were defined as CD4+IL17+ T cells, while Treg cells were defined as CD4+CD25highFoxp3+ T cells, with the Treg subsets classified as follows: activated Treg (CD45RA-Foxp3high), non-suppressive Treg (CD45RA-Foxp3low) and resting Treg (CD45RA''Foxp3low). FMO controls were used to properly identify the CD45RA', CD25', IL17', Foxp3' populations.

Statistics
Mann-Whitney tests were used to compare the frequencies of the above-cited T cell subsets among the studied groups. Correlations were calculated using Spearman regression. P-values < 0.05 were considered significant. All analyses were carried out using GraphPad Prism v.7.

Results
Clinical and demographic characteristics
The clinical and demographic characteristics of the studied groups are shown in Table 1. No significant difference in age was found between the groups, but ECs had a significantly higher frequency of women than VCs and cART (79% vs. 31% vs. 39%). The plasma VL had a median of 450 copies/ml in VCs, but undetectable levels were found in all ECs and cART. Higher

|                               | HIV-neg (n = 18) | cART (n = 18) | EC (n = 14) | VC (n = 13) |
|-------------------------------|-----------------|---------------|-------------|-------------|
| Age, median [IQR]             | 37.1 [29.80–49.55] | 44.5 [38.28–50.05] | 42.8 [37.60–58.8] | 42.7 [37.60–47.05] |
| Gender (%M)                   | 50              | 61            | 21          | 69          |
| Viral load (copies/ml, median [IQR]) | N/A            | <40 [<40]     | <40 [<40–87] | 450 [224.0–881.5] |
| CD4+ T cells count (cells/mm³), median [IQR] | 831 [741.80–1227] | 853 [745–1006] | 1165 [888–1486] | 830 [605–1365] |
| Years since HIV-1 diagnosis, median [IQR] | N/A            | 10.9 [8.7–15.1] | 8.5 [4.0–15.4] | 10.4 [5.4–14.55] |

HIV-neg: HIV-1-uninfected individuals; EC: Elite controllers; VC: viremic controllers; cART: Chronic HIV-1 infected individual under cART and at least two years of VL below limit. N/A: not applicable. P-value was obtained using the Mann-Whitney test.

* p = 0.0079, comparing EC with cART group.

https://doi.org/10.1371/journal.pone.0228745.t001
CD4⁺ T cell counts were observed in ECs compared with cART (p = 0.0079). Detailed CD4⁺ T cells/mm³ and VL profiles of the ECs and VCs during the long-term follow-up were previously described [58,59]. ECs and VCs had medians of 8.5 and 10.4 years of HIV diagnosis time, respectively.

When evaluating the level of activation in CD4⁺ T cells (CD4⁺CD38⁺HLA-DR⁺), ECs showed similar frequencies of activated cells as those observed for the HIV-neg group. On the other hand, the VC and cART groups presented a higher frequency of these activated cells when compared to the EC (p < 0.0001 for both groups) and HIV-neg (p < 0.0001 and p = 0.0003, respectively) groups (Fig 1A). In relation to activated CD8⁺ T cells (CD8⁺CD38⁺HLA-DR⁺), VCs presented higher levels of activation in comparison with all other groups (p < 0.0001 for ECs and HIV-neg; p = 0.0002 for cART) (Fig 1B). The cART group presented higher frequencies of activated CD8⁺ T cells only when compared with HIV-neg individuals (p = 0.0003). As observed for the activated CD4⁺ T cell subset, similar frequencies of activated CD8⁺ T cells were found in the EC and HIV-neg groups.

### Frequency of naïve, memory and effector CD4⁺ and CD8⁺ T cell subsets

Phenotypic analyses were performed to compare the frequencies of distinct T cell subsets (TN, TSCM, TCM, TTM, TEM, and TEFF) among the studied groups for both the CD4⁺ and CD8⁺
T cell compartments. When we evaluated CD4+ T cell subsets (Fig 1C), ECs presented similar levels of all subsets compared to HIV-neg, except for TTM cells, for which a significantly lower level was observed (p = 0.0304). VCs presented higher frequencies of TEFF (p = 0.0062), TN (p = 0.0111) and TSCM cells (p = 0.0315), but lower frequencies of TTM (p = 0.0032) and TCM cells (p = 0.0020) when compared to the HIV-neg group.

Among the CD8+ T cell subsets (Fig 1D), ECs presented higher frequencies of long-lived TSCM cells (p = 0.0139) than HIV-neg, while VCs presented a higher frequency of TEFF cells (p = 0.0007) in comparison to HIV-neg.

**Frequency of total Treg cells and Treg subsets**

We evaluated the frequency of total Treg cells, and their activated, resting, and non-suppressive subsets (Fig 2). Both ECs and VCs presented lower levels of total Treg cells compared to HIV-neg (p = 0.0018 and p = 0.0001, respectively) and cART groups (p = 0.032 and p = 0.006, respectively) (Fig 2A). When analyzing the Treg subsets, ECs presented higher frequencies of activated Treg cells than the cART (p = 0.037) or HIV-neg (p = 0.003) groups (Fig 2B) and, inversely, a lower frequency of resting Treg cells than the cART (p = 0.008) or HIV-neg (p = 0.036) groups (Fig 2C). Similar frequencies of non-suppressive Treg cells were observed for all groups (Fig 2D). We observed an inverse correlation between total Treg and CD8+ T cell activation (r = -0.3607; p < 0.004), but we did not detect correlations between Treg subsets and CD4+ T cell activation (S1 Fig).

**Frequency of Th17 cells and Th17/Treg ratio**

We also analyzed the frequencies of Th17 cells and the Th17/Treg ratio among the studied groups (Fig 3). ECs presented higher levels of Th17 cells and Th17/Treg ratios when compared to the HIV-neg (p = 0.048 and p = 0.002) and cART (p = 0.009 and p = 0.007) groups. Although no statistically significant differences were observed when VCs were compared to the other groups, VCs presented higher Th17/Treg ratios than the cART (p = 0.004) and HIV-neg groups (p = 0.001). We observed an inverse correlation between Th17 frequencies and total Tregs (r = -0.2515; p = 0.04, S1 Fig).

**Discussion**

In the present study, we evaluated parameters related to the immune activation state of T cells and the balance of Th17/Treg cells in HICs with different levels of viral replication control to evaluate immunologic factors related to the better infection control. Although most HIV-infected individuals present an immunological dysregulation characterized by alterations in the frequency of T cell subsets, excessive and systemic immune activation/inflammation and changes in the intestinal mucosa [2,4,60], HICs have a more preserved immunological system and represent a model of spontaneous infection control [61–63].

By evaluating the frequency of CD38+HLA-DR+ cells in both CD4+ and T CD8+ T cells, we identified higher levels of activated T cells in VCs compared to the other studied groups, indicating the contribution of viral replication to the increase in immune activation even among individuals with low but detectable viremia. Immune activation during chronic HIV infection is one of the major issues associated with viral persistence and disease progression, leading to CD4 T cell depletion, enhancement of viral replication, and exhaustion and senescence of T cells [2]. This setting results in an impairment of the immune response, despite the increased activity, as shown by the use of serum and cellular activation markers as predictors of AIDS [64–68]. We also observed higher frequencies of CD4+ and CD8+ TEFF cells in VCs, indicating an increase in T cell differentiation. These data highlight the need for increased care and
surveillance of individuals with low-level viremia since even lower levels of antigenic stimulation have a negative effect on the immunological system.

Activation levels were lower among cART-treated patients than VCs, pointing to the undeniable positive effect of cART. In the last decades, drugs with higher genetic barriers and new regimens have been developed [69], bypassing drug resistance issues, improving the survival and quality of life of infected individuals [70–72] and decreasing transmission rates [73,74], which supports the expansion of cART coverage and early initiation. In this context, antiretroviral therapy could improve immunological health in viremic controllers, lowering activation levels as observed in cART individuals. On the other hand, activation levels in cART individuals were higher than those observed in HIV-negative individuals, consistent with previous studies that indicate that cART alone cannot normalize T cell activation [5–8,75]. These data reinforce the idea that, although driven by HIV infection, immune activation is boosted by factors that go beyond the direct effects of viral replication. Bystander activation of CD8+ T cells in HIV infection has been observed to be associated with the reactivation of other viruses [76,77] and with the circulation of proinflammatory cytokines [78,79], while microbial translocation due to CD4+ T cell depletion in the gut mucosa is considered one of the major mechanisms driving immune activation [80–82]. Besides, suboptimal penetration of drugs in anatomical sites such as the central nervous system, GALT, and lymph nodes is associated with persistence of viral replication in those tissues despite plasma viral load <LDL [83–86].

Moreover, our study showed that ECs had low levels of activated T cells, similar to those observed for HIV-negative individuals. Although these results contrast with other studies that showed higher T cells activation in ECs [14–16], the normalized frequencies observed here in patients with long-term control of infection are a signal of immune preservation at a magnitude that is not achieved even with antiretroviral therapy, as most of our studied individuals had long-term HIV infection. The higher frequencies of CD8+ TCM cells in ECs found in our study also point towards this hypothesis, as others have shown the importance of this population to the maintenance of the immune response [87,88]. Also, lower activation levels may not impair the immune response against HIV as other studies have shown that, despite the activation levels, ECs present efficient cytotoxic and HIV-specific response [89]. Together, these data suggest a better immune response in ECs related more to increased efficiency than to increased magnitude.

In addition to the increase in CD8+ TCM frequency when compared with that in cART, we also detected an increased frequency of TSCM cells in ECs compared with HIV-neg. TSCM cells were identified as memory T cells characterized by the increased expression of naïve markers and presenting an increased proliferative capacity and self-renewal potential [90]. Despite the susceptibility of TSCM cells to HIV-1 infection [91], the proportion of CD8+ TSCM cells has been previously inversely correlated to viral replication, and immune activation [92], which is in agreement with our study, and the preservation of the CD4+ TSCM population was associated with a better prognosis in both HIV-1 and SIV infection [92,93]. Our data here also support the association between the maintenance of CD4+ TSCM cells at normal levels with better control of infection.
Fig 3. Th17 cell frequencies and Th17/Treg ratio in HICs and control groups. Frequencies of Th17 cells (CD4+IL17+) among the studied groups are shown in the graph. (B) Th17/Treg ratios are shown in the graph. The Th17/Treg ratio was calculated by using the frequencies of both populations concerning the CD4+ compartment. P-values were calculated using the Mann-Whitney test in GraphPad Prism and are represented as follows: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

https://doi.org/10.1371/journal.pone.0228745.g003
In addition to alterations in classical naïve, memory and effector T cell subsets, we also investigated the frequencies of both Th17 and Treg cells, as these cells influence the activation of effector T cell profiles in different settings. In our study, we observed lower frequencies of total Treg cells in both HIC groups when compared to the cART and the HIV-neg groups. We also observed a negative correlation between the frequency of total Tregs and activated CD8⁺ T cells, highlighting the immunosuppressive function of these cells. While this association indicates a positive effect for the increase in the frequency of these cells to control the exacerbated immune activation due to HIV infection [28,35,42], several studies have shown a correlation between higher Treg frequencies and increased viral load and progression to AIDS [19–28].

Although this duality indicates negative effects in the long term in the context of HIV infection, the relationship between Tregs and immune activation could be a useful tool for the development of alternative strategies aiming at reservoir elimination [94]. The depletion of Tregs could be used as a latency reversal strategy to induce HIV replication from reservoirs, contributing to the “shock” needed in “shock and kill” strategies. For example, Treg depletion in HIV-infected humanized mice led to viremia rebound under cART followed by a reservoir decrease in lymphoid tissue [95], while Treg depletion in the NHP model lead to viral rebound and increase in the SIV-specific response [96].

Although some studies observed higher Treg frequencies or absolute counts in HICs compared to HIV-negative individuals [32,97], the majority showed lower [98,99] or similar [33,34,42,89,100] levels of Treg cells among HICs vs. healthy subjects. In this context, the low frequencies of Treg cells in HICs observed in this study and others point towards the preservation of immune responsiveness in these individuals.

Based on CD45RA and Foxp3 expression, Treg cells can be further separated into three different subsets: activated, resting, and non-suppressive Treg cells. Despite the lower frequencies of total Tregs, we observed an increased frequency of activated Tregs and a decrease in resting Tregs in ECs when compared to control groups, as it was observed by Gaardbo et al. [101]. Together, these results indicate that the balance between the different Treg subsets could have an important role in HIV pathogenesis and that the influence of Tregs on disease progression goes beyond the increase in the total Treg population.

Evidence of a preserved immune system in HICs was also observed for Th17 cells. Here, we observed higher frequencies of these cells in the peripheral blood in both ECs and VCs compared with both the HIV-neg and cART groups. Th17 cells are important in the context of HIV infection due to their participation in the host defense processes against several pathogens in the gut tissue. Besides, Th17 cells also induce epithelial regeneration [49], helping to maintain the physical integrity of the mucosal barrier. The GALT is a major site of HIV replication and suffers a massive depletion of CD4⁺ T cells early in the infection [102,103]. This setting leads to a pro-inflammatory state that disrupts the gut mucosal barrier and enhances microbial translocation. The increase in microbial translocation, as previously stated, is believed to be one of the most significant causes of the increased immune activation observed in HIV-infected patients [80,81,104], highlighting the importance of Th17 cells for the control of immune activation in the context of HIV infection.

In general, frequencies of Th17 cells correlate negatively with the plasma viral load and positively with CD4⁺ T cell counts, and low frequency of this subset has been observed in HIV-infected patients with progressive disease [33,53–56,105], indicating impairment of the gut immune response. Falivene et al. demonstrated the prognostic value of Th17 cell frequency, showing that lower frequencies of Th17 cells and higher frequencies of activated cells were observed in acutely infected individuals who progress faster to AIDS [33]. In contrast, higher baseline Th17 frequencies in individuals undergoing acute infection are associated with
enhancement of the HIV-specific T cell response [33]. Among HICs or LTNPs, frequencies of Th17 cells are normally similar to those observed in HIV-1-uninfected individuals [33,34,54,106]. In the present study ECs, but not VCs, showed higher frequencies of Th17 cells compared to the HIV-neg and cART-treated controls, indicating a protective role of Th17 cells in HIV-1 infection.

Beyond the individual dynamic of Th17 and Treg subsets, we also observed an inverse correlation between the frequency of Th17 and Treg cells, as expected, since these cells share development pathways [57]. Our data regarding the Th17/Treg ratio on both HIC groups agreed to previous observations that found higher ratios in individuals with natural control of infection in comparison to typical progressors or HIV-negative individuals [32–34]. Overall, this preservation of the Th17/Treg ratio in both HIC groups indicates the preservation of the immune response.

Conclusions
Our data showed that ECs have low levels of activated T cells and a high frequency of activated Treg cells, which can contribute to lower immune activation in these individuals. In addition, the high frequency of Th17 cells in ECs can be indicative of a preserved mucosal response.

Supporting information
S1 Fig. Significant correlations involving the frequency of total Tregs. (A) Correlation between the frequencies of total Tregs and activated CD8+ T cells. (B) Correlation between the frequencies of total Tregs and Th17 cells. R and p-values are shown for each correlation. Dots related to each studied group are coloured according to legend on Fig 1. (TIF)

S1 Table. Raw data obtained at the study. (XLSX)

Acknowledgments
We thank the patients, nurses, and clinicians who participated in the study. We also thank Egydio Sampaio for support in the recruitment of patients and all INI staff from the blood collection sector. Finally, we thank CD4+ T cell counts and HIV-1 viral load clinical services from the Brazilian Ministry of Health National Network, and the FIOCRUZ PDTIS Flow Cytometry Platform (RPT08A).

Author Contributions
Conceptualization: Fernanda H. Côrtes.
Data curation: Fernanda H. Côrtes.
Formal analysis: Diogo G. Caetano, Hury H. S. de Paula, Fernanda H. Côrtes.
Investigation: Diogo G. Caetano, Hury H. S. de Paula, Gonzalo Bello, Brenda Hoagland, Larissa M. Villela, Beatriz Grinsztejn, Valdilea G. Veloso, Mariza G. Morgado, Monick L. Guimarães, Fernanda H. Côrtes.
Methodology: Diogo G. Caetano, Hury H. S. de Paula, Fernanda H. Côrtes.
Supervision: Gonzalo Bello, Mariza G. Morgado, Monick L. Guimarães.
Writing – original draft: Diogo G. Caetano, Fernanda H. Côrtes.
Writing – review & editing: Diogo G. Caetano, Hury H. S. de Paula, Gonzalo Bello, Brenda Hoagland, Larissa M. Villela, Beatriz Grinsztejn, Valdílea G. Veloso, Mariza G. Morgado, Monick L. Guimarães, Fernanda H. Côrtes.

References

1. Deeks SG, Walker BD. Human Immunodeficiency Virus Controllers: Mechanisms of Durable Virus Control in the Absence of Antiretroviral Therapy. Immunity. Cell Press; 2007; 27: 406–416. https://doi.org/10.1016/j.immuni.2007.08.010 PMID: 17892849

2. Moir S, Chun T-W, Fauci AS. Pathogenic Mechanisms of HIV Disease. Annu Rev Pathol Mech Dis. 2011; 6: 223–248. https://doi.org/10.1146/annurev-pathol-011110-130254 PMID: 21034222

3. Sokoya T, Steel HC, Nieuwoudt M, Rossouw TM. HIV as a Cause of Immune Activation and Immuno-senescence. Mediators Inflamm. Hindawi Limited; 2017; 2017. https://doi.org/10.1155/2017/6825493 PMID: 29209103

4. Douek DC, Picker LJ, Koup RA. T CELL DYNAMICS IN HIV-1 INFECTION. Annu Rev Immunol. 2003; 21: 265–304. https://doi.org/10.1146/annurev.immunol.21.120601.141053 PMID: 12524385

5. Lederman MM, Calabrese L, Funderburg NT, Clagett B, Medvik K, Bonilla H, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. Oxford University Press; 2011; 204: 1217–26. https://doi.org/10.1089/infectdis.jir507 PMID: 21917895

6. Almeida C-AM, Price P, French MAH. Brief Communication: Immune Activation in Patients Infected with HIV Type 1 and Maintaining Suppression of Viral Replication by Highly Active Antiretroviral Therapy. AIDS Res Hum Retroviruses. Mary Ann Liebert, Inc.; 2002; 18: 1351–1355. https://doi.org/10.1089/088922202320935429 PMID: 12487806

7. French MA, King MS, Tschampa JM, da Silva BA, Landay AL. Serum Immune Activation Markers Are Persistently Increased in Patients with HIV Infection after 6 Years of Antiretroviral Therapy despite Suppression of Viral Replication and Reconstitution of CD4+ T Cells. J Infect Dis. Narnia; 2009; 200: 1212–1215. https://doi.org/10.1086/605890 PMID: 19728788

8. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T Cell Activation Is Associated with Lower CD4+ T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy. J Infect Dis. Narnia; 2003; 187: 1534–1543. https://doi.org/10.1086/374786 PMID: 12721933

9. Ghiglione Y, Falivene J, Ruiz MJ, Laufer N, Socías ME, Cahn P, et al. Early skewed distribution of total and HIV-specific CD8+ T-cell memory phenotypes during primary HIV infection is related to reduced antiviral activity and faster disease progression. PLoS One. 2014; 9. https://doi.org/10.1371/journal.pone.0104235 PMID: 25093660

10. Fromentin R, Filali-Mouhim A, Ahlers J, Yassine-Diab B, Boussel M-R, Takaha H, et al. Programmed Death-1 is a Marker for Abnormal Distribution of Naive/Memory T Cell Subsets in HIV-1 Infection. J Immunol. 2013; 191: 2194–2204. https://doi.org/10.4049/jimmunol.1200646 PMID: 23918986

11. Burgers WA, Riou C, Mitkowska M, Maenetje P, de Assis Rosa D, Brenchley J, et al. Association of HIV-Specific and Total CD8+ T Memory Phenotypes in Subtype C HIV-1 Infection with Viral Set Point. J Immunol. 2009; 182: 4751–4761. https://doi.org/10.4049/jimmunol.0803801 PMID: 19342652

12. Rabin RL, Roederer M, Maldonado Y, Petru A, Herzenberg LA, Herzenberg LA. Altered representation of naive and memory CD8 T cell subsets in HIV-infected children. J Clin Invest. American Society for Clinical Investigation; 1995; 95: 2054–60. https://doi.org/10.1172/JCI117891 PMID: 7738172

13. Roederer M, Duba JG, Anderson MT, Raju PA, Herzenberg LA, Herzenberg LA. CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest. American Society for Clinical Investigation; 1995; 95: 2061–6. https://doi.org/10.1172/JCI117892 PMID: 7738173

14. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shaffer K, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008; 197: 126–33. https://doi.org/10.1086/524143 PMID: 18171295

15. Pereyra F, Lo J, Triant VA, Wei J, Buzon MJ, Fitch K V, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS. 2012; 26: 2409–12. https://doi.org/10.1097/QAD.0b013e32835a9950 PMID: 23032411

16. Krishnan S, Wilson EMP, Sheikh V, Rupert A, Mendoza D, Yang J, et al. Evidence for innate immune system activation in HIV type 1-infected elite controllers. J Infect Dis. 2014; 209: 931–9. https://doi.org/10.1093/infdis/jit581 PMID: 24185941
17. Côrtes FH, de Paula HHS, Bello G, Ribeiro-Alves M, de Azevedo SSD, Caetano DG, et al. Plasmatic Levels of IL-18, IP-10, and Activated CD8+ T Cells Are Potential Biomarkers to Identify HIV-1 Elite Controllers With a True Functional Cure Profile. Front Immunol. Frontiers Media SA; 2018; 9: 1576. https://doi.org/10.3389/fimmu.2018.01576 PMID: 30050532

18. Côrtes FH, Passaes CPB, Bello G, Teixeira SLM, Vorsatz C, Babic D, et al. HIV Controllers With Different Viral Load Cutoff Levels Have Distinct Virologic and Immunologic Profiles. JAIDS J Acquir Immune Defic Syndr. 2015; 68: 377–385. https://doi.org/10.1097/QAI.0000000000000500 PMID: 25564106

19. Andersson J, Boasso A, Nilsson J, Zhang R, Shire NJ, Lindback S, et al. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol. American Association of Immunologists; 2005; 174: 3143–7. https://doi.org/10.4049/jimmunol.174.6.3143 PMID: 15749840

20. Nilsson J, Boasso A, Velilla PA, Zhang R, Vaccari M, Franchini G, et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood. The American Society of Hematology; 2006; 108: 3808–17. https://doi.org/10.1182/blood-2006-05-021576 PMID: 16902147

21. Hunt PW, Landay AL, Sinclair E, Martinson JA, Hatano H, Emu B, et al. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. Ostrowski M, editor. PLoS One. Public Library of Science; 2011; 6: e15924. https://doi.org/10.1371/journal.pone.0015924 PMID: 21305005

22. Chase AJ, Yang H-C, Zhang H, Blankson JN, Siliciano RF. Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J Virol. American Society for Microbiology Journals; 2008; 82: 8307–15. https://doi.org/10.1128/JVI.00520-08 PMID: 18579608

23. Baker CAR, Clark R, Ventura F, Jones NG, Guzman D, Bangsberg DR, et al. Peripheral CD4 loss of regulatory T cells is associated with persistent viraemia in chronic HIV infection. Clin Exp Immunol. Wiley-Blackwell; 2007; 147: 533–9. https://doi.org/10.1111/j.1365-2249.2006.03319.x PMID: 17302904

24. Tsunemi S, Iwasaki T, Higasa S, Kakishita E, Shirasaka T, et al. Relationship of CD4+CD25+ regulatory T cells to immune status in HIV-infected patients. AIDS. 2005; 19: 879–86. https://doi.org/10.1097/01.aids.0000171401.23243.56 PMID: 15905668

25. Bi X, Suzuki Y, Gatanaga H, Oka S. High frequency and proliferation of CD4+FOXP3+ Treg in HIV-1-infected patients with low CD4 counts. Eur J Immunol. 2009; 39: 301–309. https://doi.org/10.1002/eji.200838667 PMID: 19089812

26. Suchard MS, Mayne E, Green VA, Shalekoff S, Donninger SL, Stevens WS, et al. FOXP3 Expression Is Upregulated in CD4+ T Cells in Progressive HIV-1 Infection and Is a Marker of Disease Severity. Unutmaz D, editor. PLoS One. Public Library of Science; 2010; 5: e11762. https://doi.org/10.1371/journal.pone.0011762 PMID: 20668701

27. Nikolova M, Carriere M, Jenabian M-A, Limou S, Younas M, Kök A, et al. CD39/Adenosine Pathway Is Involved in AIDS Progression. Desrosiers RC, editor. PLoS Pathog. Public Library of Science; 2011; 7: e1002110. https://doi.org/10.1371/journal.ppat.1002110 PMID: 21750674

28. Schulze Zur Wiesch J, Thomssen A, Hartjen P, Töth I, Lehmann C, Meyer-Olson D, et al. Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. J Virol. American Society for Microbiology (ASM); 2011; 85: 1287–97. https://doi.org/10.1128/JVI.01758-10 PMID: 21047964

29. Hasenkrug KJ, Chougnet CA, Dittrmer U. Regulatory T cells in retroviral infections. PLoS Pathog. 2018; 14: 1–22. https://doi.org/10.1371/journal.ppat.1006776 PMID: 29447279

30. Chevalier MF, Weiss L. The split personality of regulatory T cells in HIV infection. Blood. 2013; 121: 29–37. https://doi.org/10.1182/blood-2012-07-409755 PMID: 23043072

31. Valverde-Villegas JM, Matte MCC, Medeiros RM de, Chies JAB. New Insights about Treg and Th17 Cells in HIV Infection and Disease Progression. J Immunol Res. 2015; 2015: 1–14. https://doi.org/10.1155/2015/647916 PMID: 26568963

32. Brandt L, Benfield T, Mens H, Clausen LN, Katzenstein TL, Fomsgaard A, et al. Low level of regulatory T cells and maintenance of balance between regulatory T cells and Th17 cells in HIV-1-infected elite controllers. J Acquir Immune Defic Syndr. 2011; 57: 101–108. https://doi.org/10.1097/QAI.0b013e18215a991 PMID: 21407087

33. Faliene J, Ghiglione Y, Laufner N, Socías ME, Holgado MP, Ruiz MJ, et al. Th17 and Th17/Treg ratio at early HIV infection associate with protective HIV-specific CD8(+) T-cell responses and disease progression. Sci Rep. Nature Publishing Group; 2015; 5: 11511. https://doi.org/10.1038/srep11511 PMID: 26099972
34. Jenabian M-A, Patel M, Kema I, Kanagaratham C, Radzioch D, Thébault P, et al. Distinct Tryptophan Catabolism and Th17/Treg Balance in HIV Progressors and Elite Controllers. Unutmaz D, editor. PLoS One. Public Library of Science; 2013; 8: e78146. https://doi.org/10.1371/journal.pone.0078146 PMID: 24147117

35. Jiao Y, Fu J, Xing S, Fu B, Zhang Z, Shi M, et al. The decrease of regulatory T cells correlates with excessive activation and apoptosis of CD8+ T cells in HIV-1-infected typical progressors, but not in long-term non-progressors. Immunology. Wiley-Blackwell; 2009; 128: e366–75. https://doi.org/10.1111/j.1365-2567.2008.02978.x PMID: 19016904

36. Montes M, Sanchez C, Lewis DE, Graviss EA, Seas C, Gotuzzo E, et al. Normalization of FoxP3+ Regulatory T Cells in Response to Effective Antiretroviral Therapy. J Infect Dis. 2011; 203: 496–499. https://doi.org/10.1093/infdis/jiq073 PMID: 21177309

37. Aandahl EM, Michaelsson J, Morettow J, Hecht FM, Nixon DF. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol. American Society for Microbiology (ASM); 2004; 78: 2454–9. https://doi.org/10.1128/JVI.78.5.2454-2459.2004 PMID: 14963140

38. Eggena MP, Barugahare B, Jones N, Okello M, Mutalya S, Kityo C, et al. Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol. American Association of Immunologists; 2005; 174: 4407–14. https://doi.org/10.4049/jimmunol.174.7.4407 PMID: 15778408

39. Kinter A, McNally J, Rigglin L, Jackson R, Roby G, Fauci AS. Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals. Proc Natl Acad Sci U S A. National Academy of Sciences; 2007; 104: 3390. https://doi.org/10.1073/pnas.0611423104 PMID: 17360656

40. Hryniewicz A, Boasso A, Edghill-Smith Y, Vaccari M, Fuchs D, Venzon D, et al. CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood. The American Society of Hematology; 2006; 108: 3834–42. https://doi.org/10.1182/blood-2006-04-010637 PMID: 16896154

41. Zelinskyy G, Dietze K, Sparwasser T, Dittmer U. Regulatory T Cells Suppress Antiviral Immune Responses and Increase Viral Loads during Acute Infection with a Lymphotropic Retrovirus. PLoS Pathog. Public Library of Science; 2009; 5: e1000406. https://doi.org/10.1371/journal.ppat.1000406 PMID: 19714239

42. Angin M, Kwon DS, Streeck H, Wen F, King M, Rezai A, et al. Preserved function of regulatory T cells in chronic HIV-1 infection despite decreased numbers in blood and tissue. J Infect Dis. 2011; 203: 496–499. https://doi.org/10.1084/jem.20081463 PMID: 19204111

43. Raffatellu M, Santos RL, Verhoeven DE, George MD, Wilson RP, Winter SE, et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med. 2008; 14: 421–8. https://doi.org/10.1038/nm1743 PMID: 18376406

44. Dandekar S, George MD, Bäumler AJ. Th17 cells, HIV and the gut mucosal barrier. Curr Opin HIV AIDS. 2010; 5: 173–178. https://doi.org/10.1097/COH.0b013e328335eda3 PMID: 20543596

45. Liang SC, Tan X-Y, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006; 203: 2271–2279. https://doi.org/10.1084/jem.20061308 PMID: 16982811

46. Griffin G, Newton G, Tarrio ML, Bu D, Maganto-Garcia E, Azzucita V, et al. IL-17 and TNFα Sustain Neutrophil Recruitment During Inflammation Through Synergistic Effects on Endothelial Activation. J Immunol. NIH Public Access; 2012; 188: 6287. https://doi.org/10.4049/jimmunol.1200385 PMID: 22566565

47. Flannigan KL, Ngo VL, Geem D, Harusato A, Hirota SA, Parkos CA, et al. IL-17A-mediated neutrophil recruitment limits expansion of segmented filamentous bacteria. Mucosal Immunol. NIH Public Access; 2017; 10: 673–684. https://doi.org/10.1038/mi.2016.80 PMID: 27624780

48. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjes M, et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med. The Rockefeller University Press; 2009; 206: 1465–72. https://doi.org/10.1084/jem.20082683 PMID: 19564350

49. Cecchinato V, Trindade CJ, Laurence A, Heraud JM, Brenchley JM, Ferrari MG, et al. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol. NIH Public Access; 2008; 1: 279–88. https://doi.org/10.1038/mi.2008.14 PMID: 19079189
51. Favre D, Lederer S, Kanwar B, Ma Z-M, Proll S, Kasakov Z, et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. Public Library of Science; 2009; 5: e1000295. https://doi.org/10.1371/journal.ppat.1000295 PMID: 19214220

52. Raffatellu M, Santos RL, Verhoeven DE, George MD, Wilson RP, Winter SE, et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med. NIH Public Access; 2008; 14: 421–8. https://doi.org/10.1038/nm1743 PMID: 18376406

53. Brenchley JM, Paiardini M, Knox KS, Asher AI, Cervasi B, Asher TE, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood. 2008; 112: 2826–2835. https://doi.org/10.1182/blood-2008-05-159301 PMID: 18664624

54. Salgado M, Rallón NI, Rodrés B, López M, Soriano V, Benito JM. Long-term non-progressors display a greater number of Th17 cells than HIV-infected typical progressors. Clin Immunol. Elsevier Inc.; 2011; 139: 110–114. https://doi.org/10.1016/j.clim.2011.02.008 PMID: 21367666

55. Prendergast A, Prado JG, Kang YH, Chen F, Riddell LA, Luzzi G, et al. HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells. AIDS. 2010; 24: 491–502. https://doi.org/10.1097/QAD.0b013e3283344895 PMID: 20771976

56. Macal M, Sankaran S, Chun TW, Reay E, Flamm J, Prindiville TJ, et al. Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol. 2008; 1: 475–488. https://doi.org/10.1038/mi.2008.35 PMID: 19079215

57. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441: 235–238. https://doi.org/10.1038/nature04753 PMID: 16648838

58. de Azevedo SSD, Caetano DG, Côrtes FH, Teixeira SLM, dos Santos Silva K, Hoagland B, et al. Highly divergent patterns of genetic diversity and evolution in proviral quasispecies from HIV controllers. Retrovirology. 2017; 14: 29. https://doi.org/10.1186/s12977-017-0354-5 PMID: 28464889

59. Caetano DG, Côrtes FH, Bello G, Teixeira SLM, Hoagland B, Grinsztejn B, et al. Next-generation sequencing analyses of the emergence and maintenance of mutations in CTL epitopes in HIV controllers with differential viremia control. Retrovirology. 2018; 15: 62. https://doi.org/10.1186/s12977-018-0444-z PMID: 30201008

60. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. Pathogenesis of HIV infection: What the virus spares is as important as what it destroys. Nat Med. 2006; 12: 289–295. https://doi.org/10.1038/nm1380 PMID: 16520776

61. Sáez-Cirión A, Pancino G. HIV controllers: a genetically determined or inducible phenotype? Immuno Rev. 2013; 254: 281–94. https://doi.org/10.1111/imr.12076 PMID: 23772626

62. Mens H, Kearney M, Wiegand A, Shao W, Schønning K, Gerstoft J, et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol. 2010; 84: 12971–81. https://doi.org/10.1128/JVI.00387-10 PMID: 20926564

63. Okulicz J F. Elite Controllers and Long-term Nonprogressors: Models for HIV Vaccine Development? J AIDS Clin Res. OMICS International; 2012;03. https://doi.org/10.4172/2155-6113.1000139

64. Mildvan D, Spritzler J, Grossberg SE, Fahey JL, Johnston DM, Schock BR, et al. Serum Neopterin, an Immune Activation Marker, Independently Predicts Disease Progression in Advanced HIV-1 Infection. Clin Infect Dis. 2005; 40: 853–858. https://doi.org/10.1086/427877 PMID: 15736019

65. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi J V. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS+ death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 16: 83–92. https://doi.org/10.1097/000023949 PMID: 9358102

66. Zangerle R, Steinhuber S, Sarcletti M, Dierich MP, Wachter H, Fuchs D, et al. Serum HIV-1 RNA Levels Compared to Soluble Markers of Immune Activation to Predict Disease Progression in HIV-1 Infectected Individuals. Int Arch Allergy Immunol. 1998; 116: 228–239. https://doi.org/10.1159/00042560-199710010-00003 PMID: 9358102

67. Giorgi J V, Liu Z, Hultin LE, Cumberland WG, Hennessy K, Detels R. Elevated levels of CD38+CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 1993; 6: 904–12. PMID: 7866224

68. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter Survival in Advanced Human Immunodeficiency Virus Type 1 Infection Is More Closely Associated with T Lymphocyte Activation than with Plasma Virus Burden or Virus Chemokine Coreceptor Usage. J Infect Dis. 1999; 179: 859–870. https://doi.org/10.1086/314660 PMID: 10068581
69. Boffito M, Waters L, Cahn P, Paredes R, Kotef J, Van Wyk J, et al. Perspectives on the Barrier to Resistance for Dolatregravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection. AIDS Res Hum Retroviruses. 2019; aid.2019.0171. https://doi.org/10.1089/aid.2019.0171 PMID: 31507204

70. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, Montfort A d’Arminio, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003; 362: 22–29. https://doi.org/10.1016/S0140-6736(03)13802-0 PMID: 12853195

71. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, et al. Continued improvement in survival among HIV-infected individuals with newer forms of active antiretroviral therapy. AIDS. 2007; 21: 685–92. https://doi.org/10.1097/QAD.0b013e32820ef30c PMID: 17413689

72. Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017; 18: 256–266. https://doi.org/10.1111/hiv.12421 PMID: 27578404

73. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med. 2011; 365: 493–505. https://doi.org/10.1056/NEJMoa1105243 PMID: 21767103

74. Rodger AJ, Cambiano V, Bruen T, Vernazza P, Collins S, Degen O, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet (London, England). Elsevier; 2019; 393: 2428–2438. https://doi.org/10.1016/S0140-6736(19)30418-0 PMID: 31056293

75. Piconi S, Trabattoni D, Gori A, Parisotto S, Magni C, Meraviglia P, et al. Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. AIDS. 2010; 24: 1991–2000. https://doi.org/10.1097/QAD.0b013e3285d8e95e PMID: 20651588

76. Christensen-Quick A, Massanella M, Frick A, Rawlings SA, Spina C, Vargas-Meneses M, et al. Sub-clinical Cytomegalovirus DNA Is Associated with CD4 T Cell Activation and Impaired CD8 T Cell CD107a Expression in People Living with HIV despite Early Antiretroviral Therapy. J Virol. 2019; 93. https://doi.org/10.1128/JVI.00179-19 PMID: 31019052

77. Doisne J-M, Urrutia A, Lacaubaratz-Porret C, Goujard C, Meyer L, Chaix M-L, et al. CD8+ T Cells Speciﬁc for EBV, Cytomegalovirus, and Inﬂuenza Virus Are Activated during Primary HIV Infection. J Immunol. The American Association of Immunologists; 2004; 173: 2410–2418. https://doi.org/10.4049/jimmunol.173.4.2410 PMID: 15294954

78. Jiang W, Younes S-A, Funderburg NT, Espinosa E, Davenport MP, et al. Cycling memory CD4+ T cells in HIV disease have a diverse T cell receptor repertoire and a phenotype consistent with bystander activation. J Virol. 2014; 88: 5369–80. https://doi.org/10.1128/JVI.00017-14 PMID: 24522925

79. Biancotto A, Grivel JC, Iglehart SJ, Vanpouille C, Lisco A, Sieg SF, et al. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. 2007; 109: 4272–4279. https://doi.org/10.1182/blood-2006-11-055764 PMID: 17288912

80. Luo Z, Li M, Wu Y, Meng Z, Martin L, Zhang L, et al. Systemic translocation of Staphylococcus drives autoimmunebody production in HIV disease 11 Medical and Health Sciences 1107 Immunology. Microbiome. BioMed Central Ltd.; 2019; 7. https://doi.org/10.1186/s40168-019-0646-1 PMID: 30764863

81. Younas M, Psomas C, Reyesn C, Cezar R, Kundura L, Portales P, et al. Microbial Translocation Is Linked to a Specific Immune Activation Profile in HIV-1-Infected Adults With Suppressed Viremia. Front Immunol. 2019; 10. https://doi.org/10.3389/fimmu.2019.02185 PMID: 31572392

82. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12: 1365–1371. https://doi.org/10.1038/nm1511 PMID: 17115046

83. Cohen J. Tissue says blood is misleading, confusing HIV cure efforts. Science. American Association for the Advancement of Science; 2011. p. 1614. https://doi.org/10.1126/science.334.6063.1614 PMID: 22194536

84. Chun T, Nickle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, et al. Persistence of HIV in Gut-Associated Lymphoid Tissue despite Long-Term Antiretroviral Therapy. J Infect Dis. 2008; 197: 719–720. https://doi.org/10.1086/527324 PMID: 18260759

85. Anderson AM, Muñoz-Moreno JA, McClemont DR, Ellis RJ, Cookson D, Clifford DB, et al. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy. J Infect Dis. 2017; 215: 105–113. https://doi.org/10.1093/infdis/jiw505 PMID: 27789723

86. Popovic M, Tenner-Racz K, Pelser G, Stellbrink HJ, Van Lunzen J, Lewis G, et al. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral
104. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. Nature Publishing Group; 2006; 12: 1365–1371. https://doi.org/10.1038/nm1511 PMID: 17115046

105. Ndhlovu LC, Chapman JM, Jha AR, Snyder-Cappione JE, Pagan M, Leal FE, et al. Suppression of HIV-1 plasma viral load below detection preserves IL-17 producing T cells in HIV-1 infection. AIDS. NIH Public Access; 2008; 22: 990–2. https://doi.org/10.1097/QAD.0b013e3282ff884e PMID: 18453860

106. Ciccone EJ, Greenwald JH, Lee PI, Biancotto A, Read SW, Yao MA, et al. CD4+ T Cells, Including Th17 and Cycling Subsets, Are Intact in the Gut Mucosa of HIV-1-Infected Long-Term Nonprogressors. J Virol. 2011; 85: 5880–5888. https://doi.org/10.1128/JVI.02643-10 PMID: 21471231